Pioglitazone Effects, Dosage, and Side Effects news Actos
Pioglitazone Systematic (IUPAC) name 5-((4-(2-(5-ethyl-2-pyridinyl) ethoxy)phenyl)methyl)-,(+-)- 2,4-thiazolidinedione, Identifiers CAS number 111025-46-8 ATC code A10BG03 PubChem 4829 DrugBank APRD00653 Chemical data Formula C19H20N2O3S Mol. weight 356.44 g/mol Pharmacokinetic data Bioavailability ? Protein binding > 99% Metabolism ? Half life 3-7 hours Excretion ? Therapeutic considerations Pregnancy cat. ? Legal status ...
Wikipedia - [full article]
Resources
- Actos (Drug Digest)
- Actos Consumer Information (U.S. Food and Drug Administration)
Pioglitazone News Headlines
- New Data Show ACTOS (pioglitazone HCl) Halted Progression Of Atherosclerosis As Indicated By CIMT
MedicalNewsToday - Sat, 18 Nov 2006 02:00 EST
- Takeda Announces Submission Of Application For Additional Indication Of Actos(R) In Japan; Concomitant Therapy With Biguanides For Type 2 Diabetes
MedicalNewsToday - Sun, 28 Jan 2007 02:00 EST
- The Right Balance Drives The Field Of PPAR Agonist R&D
MedicalNewsToday - Mon, 15 Jan 2007 01:00 EST
- Takeda Announces Positive Opinion From European Regulatory Authorities For Combination Use Of Actos(R) With Insulin For Type 2 Diabetes
MedicalNewsToday - Thu, 04 Jan 2007 02:00 EST
- NovoMix® 30 Helps People With Type 2 Diabetes Achieve Recommended Blood Glucose Targets
MedicalNewsToday - Mon, 11 Dec 2006 02:00 EST
- ACTOS(R) (pioglitazone HCl) Demonstrates Significant Improvements In Cardiovascular Outcomes For High-Risk Patients With Type 2 Diabetes
MedicalNewsToday - Fri, 15 Sep 2006 12:00 EST
- New Analyses Show ACTOS(R) (pioglitazone HCl) Reduced Risk Of Secondary Stroke By Almost 50 Percent In High-Risk Type 2 Diabetes Patients
MedicalNewsToday - Mon, 04 Sep 2006 12:00 EST
- Marketing Authorisation Granted For Competactâ„¢ (pioglitazone/metformin) For Type 2 Diabetes In Europe
MedicalNewsToday - Mon, 07 Aug 2006 11:00 EST
- FDA Approves Duetact(TM) (pioglitazone HCl And Glimepiride) For The Treatment Of Type 2 Diabetes
MedicalNewsToday - Tue, 01 Aug 2006 11:00 EST
- An Oral Antidiabetic Medication Demonstrates Significant Improvements In Cardiovascular Outcomes
MedicalNewsToday - Mon, 18 Sep 2006 01:00 EST
- Stroke Reduced By Almost 50 Percent By ACTOS
MedicalNewsToday - Sat, 09 Sep 2006 03:00 EST
- Galvus Combination Lowers Blood Sugar By Up To 2.8%
MedicalNewsToday - Wed, 14 Jun 2006 03:00 EST
- ACTOS® (pioglitazone HCl) To Be Studied In New Trial
MedicalNewsToday - Tue, 13 Jun 2006 07:00 EST
- European Medicines Agency, CMPH, Initial Marketing Authorisation Applications
MedicalNewsToday - Mon, 05 Jun 2006 02:00 EST
- Takeda Submits New Drug Application For Extended-release Type 2 Diabetes Medication, ACTOplus MetTM
MedicalNewsToday - Thu, 06 Apr 2006 08:00 EST
- Joslin Researchers Reveal Mechanisms Behind A Class Of Oral Agents Used To Treat Type 2 Diabetes
MedicalNewsToday - Mon, 13 Mar 2006 07:00 EST
- Actos® (pioglitazone HCl) Reduces Heart Attacks, Strokes and Deaths in Diabetes 2 Patients
MedicalNewsToday - Tue, 13 Sep 2005 08:00 EST
- Diabetes medication pioglitazone HCl may significantly improve predictors of cardiovascular risk
MedicalNewsToday - Tue, 10 May 2005 08:00 EST
- ACTOS® (pioglitazone HCl) significantly improved components of diabetic dyslipidemia
MedicalNewsToday - Thu, 30 Jun 2005 03:00 EST
- Add-on Effects of ACTOS(r) (pioglitazone HCl)
MedicalNewsToday - Sat, 11 Jun 2005 11:00 EST